Dr. Bronner’s ramps up support of psychedelic substance use

The personal care brand believes pain and suffering could be alleviated with the regulated use of psychedelic substances

Dr. Bronner's labels outline some claimed benefits of psychedelic substances

Dr. Bronner’s has put renewed support behind the use of psychedelic substances by sponsoring this year’s Breaking Convention conference, due to be held in London, UK.

The event, held from 30 June to 2 July at the Old Royal Naval College, explores the benefits to humans of psychedelic substances and features more than 150 guest speakers on the topic.

Psychedelic substances, which include LSD and psilocin or ‘magic mushrooms’, are considered by some to provide health benefits to humans with health conditions that have proven unresponsive to traditional treatments.

The use of these substances in relation to medicine, psychology, anthropology, sociology, law, politics and the arts will be explored at the conference, now in its fourth year.

David Bronner, Cosmic Engagement Officer (CEO) of Dr. Bronner’s, said: “There is a tremendous amount of pain and suffering that could be alleviated with the regulated use of psychedelic substances.

“Our goal is to integrate the responsible use of psychedelics into society, as we open our hearts and minds to the possibility of alternative treatments and create a more understanding world.”

The personal care brand has spoken out about the claimed benefits of such substances before.

Previous support includes a pledge to donate $5m over five years to the American Multidisciplinary Association for Psychedelic Studies, which is researching the use of MDMA in untreatable cases of post-traumatic stress disorder.

Companies